AnaCardio AB is a privately held clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. The Company’s lead program AC01, a first-in-class calcium sensitizing inotrope, is an oral ghrelin mimetic small-molecule, which was in-licensed from Helsinn and is now being developed as a contractile agent in heart failure patients. The company has raised over USD 40 million to date. AnaCardio is based in Stockholm, Sweden. You can find more information about AnaCardio at www.anacardio.com.
| Website | http://www.anacardio.com |
| Employees | 27 (11 on RocketReach) |
| Address | Nanna Svartz väg 4, Innomedicum, Solna, Stockholm County 171 65, SE |
| Phone | +46 8 697 20 00 |
| Industry | Biotechnology Research |
| Keywords | Heart Failure Treatment, Cardiovascular Disease, Biopharmaceutical, Novel Drugs, Drug Development, Clinical Stage, Heart Health, Pharmaceutical Research, Biotechnology, Cardiology, Clinical Trials, Medical Research, Cardiac, Health Technology, Circulatory System, Treatment |
| Competitors | Apex Cardiology Pc, CL Laboratory LLC, CardioMed Supplies Inc., Cardiovascular Systems, Inc., HeartFlow, Inc, iRhythm Technologies International, Edwards Lifesciences, Medtronic, Varian, Masimo +26 more (view full list) |
Looking for a particular AnaCardio employee's phone or email?
Patrik Strömberg is the CEO of AnaCardio.
11 people are employed at AnaCardio.
AnaCardio is based in Solna, Stockholm County.